Evidence map›Paper›PMID 26561036›Full record

ArticleScientific reports2015

Protein receptor-independent plasma membrane remodeling by HAMLET: a tumoricidal protein-lipid complex.

Aftab Nadeem, Jeremy Sanborn, Douglas L Gettel, Ho C S James, Anna Rydström, Viviane N Ngassam, Thomas Kjær Klausen, Stine Falsig Pedersen, Matti Lam, Atul N Parikh and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 4 countries.

Aftab NadeemDepartment of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, S-223 62 Lund, Sweden.
Jeremy SanbornDepartments of Applied Science, Biomedical Engineering, and Chemical Engineering &Materials Science, University of California, Davis, CA 95616 USA.
Douglas L GettelDepartments of Applied Science, Biomedical Engineering, and Chemical Engineering &Materials Science, University of California, Davis, CA 95616 USA.
Ho C S JamesDepartment of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, S-223 62 Lund, Sweden.
Anna RydströmDepartment of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, S-223 62 Lund, Sweden.
Viviane N NgassamDepartments of Applied Science, Biomedical Engineering, and Chemical Engineering &Materials Science, University of California, Davis, CA 95616 USA.
Thomas Kjær KlausenDepartment of Biology, University of Copenhagen, Universitetsparken 13, 2100, Copenhagen, Denmark.
Stine Falsig PedersenDepartment of Biology, University of Copenhagen, Universitetsparken 13, 2100, Copenhagen, Denmark.
Matti LamDepartment of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, S-223 62 Lund, Sweden.
Atul N ParikhDepartments of Applied Science, Biomedical Engineering, and Chemical Engineering &Materials Science, University of California, Davis, CA 95616 USA.
Catharina SvanborgDepartment of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, S-223 62 Lund, Sweden.
Lund University · SEUniversity of California, Davis · USUniversity of Copenhagen · DK

Funding

Training Program in Biomolecular TechnologyT32GM008799 · NIGMS · UNIVERSITY OF CALIFORNIA DAVIS · PI LEACH, J. KENT · 2002 to 2016
$2.4M
NIGMS NIH HHS T32 GM008799NIGMS NIH HHS T32-GM008799
6 · The paper itself

Abstract

A central tenet of signal transduction in eukaryotic cells is that extra-cellular ligands activate specific cell surface receptors, which orchestrate downstream responses. This ''protein-centric" view is increasingly challenged by evidence for the involvement of specialized membrane domains in signal transduction. Here, we propose that membrane perturbation may serve as an alternative mechanism to activate a conserved cell-death program in cancer cells. This view emerges from the extraordinary manner in which HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) kills a wide range of tumor cells in vitro and demonstrates therapeutic efficacy and selectivity in cancer models and clinical studies. We identify a ''receptor independent" transformation of vesicular motifs in model membranes, which is paralleled by gross remodeling of tumor cell membranes. Furthermore, we find that HAMLET accumulates within these de novo membrane conformations and define membrane blebs as cellular compartments for direct interactions of HAMLET with essential target proteins such as the Ras family of GTPases. Finally, we demonstrate lower sensitivity of healthy cell membranes to HAMLET challenge. These features suggest that HAMLET-induced curvature-dependent membrane conformations serve as surrogate receptors for initiating signal transduction cascades, ultimately leading to cell death.

Indexed as

Signal TransductionApoptosisCell DeathCell MembraneCell Membrane PermeabilityHumansLactalbuminLigandsLipid BilayersMembrane LipidsOleic AcidsProtein Bindingras ProteinsReceptors, Cell SurfaceHAMLET complex, humanLactalbuminLigandsLipid BilayersMembrane LipidsOleic Acidsras ProteinsReceptors, Cell Surface

Identifiers

PMID26561036
PMCPMC4642337
OpenAlexW2233672061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.